The objectives of this study are to assess the safety, tolerability, clinical and microbiological efficacy and pharmacodynamics of patients who have severe pneumonia caused by Streptococcus pneumoniae after the intravenous administration of CAL02 in addition of standard of care antibiotic treatment.
Streptococcus pneumoniae is the most frequently identified pathogen of community-acquired bacterial pneumonia and its severe forms are associated with high morbidity and mortality, despite pneumococcal vaccines and medical treatment (antibiotic therapy, alone or in combination). Bacterial toxins, such as the pore-forming toxin (PFT) pneumolysin (from Streptococcus pneumoniae), are involved in the development of invasive disease and play a key role in severe and fatal complications. CAL02 offers a novel therapeutic approach by neutralising bacterial toxins, such as pneumolysin, which recognise specific microdomains on host cell membranes, called lipid rafts.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
19
Two doses of CAL02 (low-dose) administered 2 times (24 hours apart) as i.v. infusion
Two doses of CAL02 (high-dose) administered 2 times (24 hours apart) as i.v. infusion
Placebo administered administered 2 times (24 hours apart) as i.v. infusion
St Luc University Hospital
Brussels, Belgium
University Hospital Brussels
Brussels, Belgium
Clinique St Pierre
Ottignies, Belgium
CHU Jean Minjoz
Besançon, France
Frequency, severity and characteristics of adverse events after two iv. administrations of CAL02.
To determine the safety profile of CAL02
Time frame: 29 days
Clinical efficacy: cure.
Complete resolution of signs and symptoms of pneumonia
Time frame: 29 days.
Pharmacodynamic effects.
Measuring biomarkers (CRP/PCT).
Time frame: 29 days.
Microbiological efficacy.
Eradication: baseline isolate not present in repeat culture from original infection site
Time frame: 29 days.
Survival.
Assessment of 28 days all cause mortality.
Time frame: 29 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
CHD Les Oudairies
La Roche-sur-Yon, France
Hôpital Mignot
Le Chesnay, France
CHU Dupuytren
Limoges, France
Centre Hospitalier Régional d'ORLEANS
Orléans, France
CH Yves Le Foll
Saint-Brieuc, France
CHRU de Tours
Tours, France